Vaxcyte (PCVX) Competitors $33.27 +0.33 (+1.00%) Closing price 04:00 PM EasternExtended Trading$33.53 +0.26 (+0.78%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PCVX vs. SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, BPMC, and BBIOShould you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Vaxcyte vs. Its Competitors Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines BridgeBio Pharma Vaxcyte (NASDAQ:PCVX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment. Do analysts recommend PCVX or SMMT? Vaxcyte presently has a consensus target price of $136.50, suggesting a potential upside of 310.28%. Summit Therapeutics has a consensus target price of $34.67, suggesting a potential upside of 53.26%. Given Vaxcyte's stronger consensus rating and higher possible upside, equities analysts plainly believe Vaxcyte is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Summit Therapeutics 2 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.79 Which has better valuation and earnings, PCVX or SMMT? Summit Therapeutics has higher revenue and earnings than Vaxcyte. Summit Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$463.93M-$3.99-8.34Summit Therapeutics$700K23,998.85-$221.32M-$0.34-66.53 Which has more volatility & risk, PCVX or SMMT? Vaxcyte has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.01, indicating that its share price is 201% less volatile than the S&P 500. Is PCVX or SMMT more profitable? Vaxcyte's return on equity of -17.12% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -17.12% -16.26% Summit Therapeutics N/A -62.87%-51.61% Does the media prefer PCVX or SMMT? In the previous week, Summit Therapeutics had 11 more articles in the media than Vaxcyte. MarketBeat recorded 14 mentions for Summit Therapeutics and 3 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.12 beat Summit Therapeutics' score of 0.62 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of PCVX or SMMT? 96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryVaxcyte beats Summit Therapeutics on 8 of the 14 factors compared between the two stocks. Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCVX vs. The Competition Export to ExcelMetricVaxcyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.25B$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-8.3421.3126.1719.90Price / SalesN/A278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book1.257.518.055.38Net Income-$463.93M-$55.05M$3.15B$248.50M7 Day Performance0.54%2.45%1.85%2.97%1 Month Performance-5.00%7.33%4.81%6.02%1 Year Performance-56.26%5.38%34.86%20.39% Vaxcyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCVXVaxcyte1.7866 of 5 stars$33.27+1.0%$136.50+310.3%-57.2%$4.25BN/A-8.34160News CoveragePositive NewsSMMTSummit Therapeutics2.6356 of 5 stars$20.39-0.8%$35.09+72.1%+160.4%$15.14B$700K-59.97110Analyst UpgradeITCIIntra-Cellular Therapies0.908 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.8891 of 5 stars$20.68-2.3%$39.17+89.4%-16.5%$13.26B$3.12B11.752,682High Trading VolumeRDYDr. Reddy's Laboratories2.8098 of 5 stars$15.31+0.5%$16.95+10.7%-1.0%$12.78B$3.81B23.2027,811ASNDAscendis Pharma A/S3.5662 of 5 stars$175.78-0.6%$220.67+25.5%+28.4%$10.75B$393.54M-27.991,017Positive NewsVTRSViatris3.0472 of 5 stars$8.85-0.2%$10.40+17.5%-13.3%$10.39B$14.74B-2.7932,000QGENQiagen4.2068 of 5 stars$46.72-0.1%$47.74+2.2%+23.2%$10.39B$2.00B117.145,765Dividend AnnouncementMRNAModerna4.3608 of 5 stars$25.67-0.9%$46.61+81.6%-75.3%$9.93B$3.14B-2.945,800Trending NewsOptions VolumeBPMCBlueprint Medicines1.5462 of 5 stars$128.40+0.2%$128.06-0.3%+17.5%$8.29B$508.82M-51.98640High Trading VolumeBBIOBridgeBio Pharma4.7139 of 5 stars$42.17+1.1%$56.67+34.4%+69.8%$8.01B$127.42M-11.95400Analyst ForecastInsider Trade Related Companies and Tools Related Companies Summit Therapeutics Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Viatris Competitors Qiagen Competitors Moderna Competitors Blueprint Medicines Competitors BridgeBio Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCVX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PCVX Stock Alerts